Analysts See $-0.22 EPS for Soligenix, Inc. (SNGX)

March 21, 2018 - By marketbeat

 Analysts See $ 0.22 EPS for Soligenix, Inc. (SNGX)

Analysts expect Soligenix, Inc. (NASDAQ:SNGX) to report $-0.22 EPS on March, 26.They anticipate $0.05 EPS change or 29.41 % from last quarter’s $-0.17 EPS. After having $-0.17 EPS previously, Soligenix, Inc.’s analysts see 29.41 % EPS growth. It closed at $2.01 lastly. It is down 63.52% since March 21, 2017 and is downtrending. It has underperformed by 80.22% the S&P500.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company has market cap of $17.57 million. It operates through two divisions, BioTherapeutics and Vaccines/BioDefense. It currently has negative earnings. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.